Attovia Therapeutics, Inc. (ATTO) stock
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$15.58+0.05 (+0.32%)
Close on Nov 19, 2026Market cap $711.25MP/E –Yield –
Attovia Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.02M | – |
| Q2 FY2026 | Jun 30, 2026 | -$21.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.62M | – |
See a number that looks wrong?